CAR-T治疗CT0596在其他治疗失败后,对2名罕见、侵袭性白血病患者作出深刻反应。 CAR-T therapy CT0596 achieved deep responses in two patients with rare, aggressive leukemia after other treatments failed.

CARSgen(CARSgen)以CAR-T为目标的CAR-T疗法CT0596引发了对两名患有罕见、攻击性强的初级血浆细胞白血病的病人的严格全面反应,这些病人已经用尽了先前的治疗。 CARsgen’s allogeneic BCMA-targeted CAR-T therapy CT0596 induced stringent complete responses in two patients with rare, aggressive primary plasma cell leukemia who had exhausted prior treatments. 两者在四周内都没有达到可检测到的最起码的残余疾病,同时持续有力扩大CAR-T细胞。 Both achieved no detectable minimal residual disease within four weeks, with robust and persistent CAR-T cell expansion. 治疗相关的副作用,包括细胞因子释放综合征和严重的细胞衰竭,均通过标准治疗得到控制. Treatment-related side effects, including cytokine release syndrome and severe cytopenias, were managed with standard therapies. 结果显示潜在的功效,但需要进行更大的研究来证实调查结果。 Results suggest potential efficacy, but larger studies are needed to confirm findings.